October 17th, 2006. The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma
The methods used were immunohistochemistry, Western blotting, and RT-PCR. DMPM specimens showed significantly higher expression of p75 (P.
October 5th, 2006. Drug targets to pro-angiogenetic factors with special reference to primary peritoneal mesothelioma
Our results suggest that PPM is an angiogenesis-dependent neoplasia. Therefore, antiangiogenic compounds should be tested particularly in those patients with highly vascularized PPM.
September 25th, 2006. Biology and management of malignant pleural mesothelioma
Studies with anti-angiogenesis agents are ongoing. An improvement of the knowledge of major molecular pathways involved in malignant mesothelioma is needed in order to define proper targets for the systemic treatment of this disease.
March 16th, 2006. Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor
Treatment with cisplatin, but not gemcitabine, significantly inhibited the production of pleural effusions, but it was not effective for thoracic tumors, consistent with chemotherapy refractory characteristics of MPM in patients. Our patient-like orthotopic model using EHMES-10 cells overexpressing VEGF and its receptor may be useful for examining the molecular pathogenesis of MPM and may contribute to the development of novel treatment strategies for MPM.
December 6th, 2005. Antiangiogenic therapies for mesothelioma
Several clinical trials are currently evaluating the efficacy of inhibitors of angiogenesis in mesothelioma. This article details the preliminary results of these trials and future directions.
August 24th, 2004. Effect of inhibition of multiple steps of angiogenesis in syngeneic murine pleural mesothelioma
Conclusions: In this murine model, inhibiting multiple mechanisms of angiogenesis using two agents is a more effective antineoplastic strategy than using either agent alone. In addition, instillation of antiangiogenic gene transfer vectors into the pleural space does not result in histologic evidence of pulmonary emphysema.
- Home
- About Mes-Line
- Categories
- Contact Us
- Glossary
- Processor
Article Categories
- Full Archive
- Type of Assessment:
- Case Study
- Causation
- Diagnosis & Differentiation
- Epidemiological
- General
- Staging
- Survival
- Symptoms & Symptom Management
- Treatment
- Angiogenesis
- Chemotherapy
- Bevacizumab (Avastatin)
- Carboplatin
- Cisplatin (Platinol ®)
- Coramsine
- Cyclophosphamide
- Cycloplatam
- Docetaxel (Taxotere)
- Doxorubicin
- Epirubicin (Ellence)
- Erlotinib (Tarceva®)
- Gemcitabine (Gemzar)
- Imatinib Mesylate (Gleevec/Glivec)
- Irinotecan
- melphalan
- mitomycin-C
- Oxaliplatin (Eloxatin)
- Oxaliplatine
- paclitaxel
- Pemetrexed (Alimta)
- Raltitrexed (Tomudex)
- Ranpirnase (Onconase)
- Selenite
- Sunitinib
- Taurolidine
- Vinorelbine
- Determining Efficacy
- EGFR
- Gene Therapy
- Immune-based Therapies
- Intraperitoneal Chemotherapy
- Intrapleural Chemotherapy
- Kinase Inhibitors
- New & Novel
- Photodynamic Therapy (PDT)
- pleurodesis
- Proteasome inhibitors
- Radiation
- Radiofrequency Ablation
- Signal Transduction Inhibitors
- Surgery
- Trimodality Therapy
- Type of Mesothelioma:
Annual Archives:
-
You are currently browsing the archives for the Angiogenesis category.
